Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
← catalyst calendarNCT04336241 · readout in 73 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
36estimated
Sites
6
Countries
Spain, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-17 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Interventions
- Biological: RP2
- Biological: nivolumab — also filed as Opdivo
Primary outcomes
what the primary-completion date above is the date OFPercentage of adverse events (AEs)
measured From Day 1 up to 60 days after last dose
Percentage of serious adverse events (SAEs)
measured From Day 1 up to 60 days after last dose
Percentage of dose limiting toxicities (DLTs)
measured From Day 1 up to 30 days after last dose.
Percentage of treatment emergent adverse events (TEAEs)
measured From Day 1 up to 60 days after last dose.
Percentage of TEAEs ≥ Grade 3
measured From Day 1 up to 60 days after last dose.
Percentage of events requiring withdrawal
measured From Day 1 up to last dose (up to 8 weeks for dose escalation phase and up to 2 years for expansion phase)).
Maximum tolerated dose (MTD) of RP2
measured 7 months
Recommended Phase 2 dose (RP2D) of RP2
measured 7 months
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed